Oxford, UK-based SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.
SpyBiotech’s proprietary SpyCatcher/SpyTag is a platform technology which allows antigens to be displayed onto virus-like particles (VLPs) with a covalent, irreversible bond in a highly stable and effective way with specific orientation/epitope presentation and high density. The technology can be used for an exceptionally broad range of applications in vaccine development and has established proof of concept data in viral, bacterial, parasitic diseases as well as chronic diseases and cancer.
"It is amazing being part of a project which presents an opportunity to develop treatments for a broad range of diseases,” said Dámaso Molero, chief executive officer, 3P Biopharmaceuticals. “We are helping to support manufacturing which we believe will open the door for pioneering vaccines which could offer a hope for improving the lives of many people. That is extremely exciting.”
Genevieve Labbe, senior scientist and GMP project manager, SpyBiotech, said, “It’s critical to have a trusted partner in place for cell line and cGMP production. SpyBiotech is looking forward to advancing this product and we are delighted to be working with 3P Biopharmaceuticals, a leading CDMO.”
Through this partnership, 3P Biopharmaceuticals will once again demonstrate its capacity to carry out processes and manufacturing of molecules developed for diverse therapeutic applications, helping to consolidate its competitive position as one of the most trusted CDMOs in Europe.